Literature DB >> 8436260

Raised serum apolipoprotein (a) in active diabetic retinopathy.

M Maioli1, G Tonolo, A Pacifico, M Ciccarese, P Brizzi, E M Kohner, M Porta.   

Abstract

Progressive capillary occlusion often leads to severe retinopathy within 15-20 years of the onset of Type 1 (insulin-dependent) diabetes mellitus. Lipoprotein(a), a complex formed by apolipoprotein(a), apo B-100 and lipids, is considered an independent, genetically determined, predictor of cardiovascular disease. It may have antifibrinolytic properties in view of its similarity to plasminogen. To test the hypothesis that circulating lipoprotein(a) is associated with the process that leads to clinically active diabetic retinopathy, we measured the circulating levels of apolipoprotein(a) (which are strictly correlated with those of lipoprotein(a)) in two groups of patients with Type 1 diabetes of at least 15 years duration: 25 with active retinopathy and 27 without clinically detectable retinal lesions. Thirty-eight healthy subjects of the same age and sex served as controls. Serum apolipoprotein(a) was higher in the patients with active retinopathy (36(2-193) U/dl, geometric mean and range) than in those without clinically detectable retinal lesion (17(1-160)) and the control subjects (14(0-115)), p < 0.01 in both cases. The distribution of apolipoprotein(a) levels was skewed to the left, as expected, in the patients without clinically evident retinal lesions and the control groups, but there was a bimodal trend of distribution among those with active retinopathy. The levels of glycated haemoglobin were similar in the two groups of diabetic patients, and no significant differences were found for total and HDL cholesterol, triglycerides or apolipoproteins A1 and B between them and the control subjects. These preliminary results suggest that serum apolipoprotein(a) is elevated in patients with active retinopathy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436260     DOI: 10.1007/bf00399100

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  8 in total

1.  Lipoprotein(a). Thrombogenesis linked to atherogenesis at last?

Authors:  J Scott
Journal:  Nature       Date:  1989-09-07       Impact factor: 49.962

Review 2.  Do genetic factors play a role in the pathogenesis of diabetic microangiopathy?

Authors:  J Barbosa; B Saner
Journal:  Diabetologia       Date:  1984-11       Impact factor: 10.122

3.  Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria.

Authors:  A J Jenkins; J S Steele; E D Janus; J D Best
Journal:  Diabetes       Date:  1991-06       Impact factor: 9.461

Review 4.  The mysteries of lipoprotein(a).

Authors:  G Utermann
Journal:  Science       Date:  1989-11-17       Impact factor: 47.728

5.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Arch Ophthalmol       Date:  1984-04

6.  Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors.

Authors:  T Jensen; K Borch-Johnsen; A Kofoed-Enevoldsen; T Deckert
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

7.  Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects.

Authors:  S M Haffner; K R Tuttle; D L Rainwater
Journal:  Diabetes Care       Date:  1991-04       Impact factor: 19.112

8.  Serum lipids and apolipoproteins A-I, A-II, and B in hyperthyroidism before and after treatment.

Authors:  E Muls; V Blaton; M Rosseneu; E Lesaffre; G Lamberigts; P De Moor
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

  8 in total
  7 in total

1.  Serum lipoprotein (a) in type 1 diabetic children and adolescents: relationships with HbA1c and subclinical complications.

Authors:  D Willems; H Dorchy; D Dufrasne
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

Review 2.  Dyslipidemia and diabetic retinopathy.

Authors:  Yo-Chen Chang; Wen-Chuan Wu
Journal:  Rev Diabet Stud       Date:  2013-08-10

3.  Is it time to change the goals of lipid management in type 1 diabetes mellitus? Changes in apolipoprotein levels during the first year of type 1 diabetes mellitus. Prospective InLipoDiab1 study.

Authors:  Aleksandra Cieluch; Aleksandra Uruska; Marcin Nowicki; Ewa Wysocka; Paweł Niedźwiecki; Agata Grzelka-Woźniak; Justyna Flotyńska; Dorota Zozulińska-Ziółkiewicz
Journal:  Arch Med Sci       Date:  2020-10-29       Impact factor: 3.707

4.  Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.

Authors:  K Hirata; K Saku; S Jimi; S Kikuchi; H Hamaguchi; K Arakawa
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

5.  Lipoprotein(a), homocysteine, and retinal arteriosclerosis.

Authors:  Amir Ghorbanihaghjo; Alireza Javadzadeh; Hassan Argani; Nariman Nezami; Nadereh Rashtchizadeh; Mandana Rafeey; Mohammad Rohbaninoubar; Babak Rahimi-Ardabili
Journal:  Mol Vis       Date:  2008-09-15       Impact factor: 2.367

6.  Associations between serum apolipoproteins, urinary albumin excretion rate, estimated glomerular filtration rate, and diabetic retinopathy in individuals with type 2 diabetes.

Authors:  Jin Ook Chung; Seon-Young Park; Dong Hyeok Cho; Dong Jin Chung; Min Young Chung
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Lipoprotein(a) serum levels in diabetic patients with retinopathy.

Authors:  Giulia Malaguarnera; Caterina Gagliano; Claudio Bucolo; Marco Vacante; Salvatore Salomone; Michele Malaguarnera; Daniela Giovanna Leonardi; Massimo Motta; Filippo Drago; Teresio Avitabile
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.